A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 48.2B | 48.2B | 48.3B | 45.0B | 46.2B | 46.4B |
| Net Income | 7.1B | 7.1B | -8.9B | 8.0B | 6.3B | 7.0B |
| EPS | $3.46 | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
| Free Cash Flow | 12.8B | 12.8B | 13.9B | 12.7B | 11.9B | 15.2B |
| ROIC | 15.2% | 15.1% | -14.0% | 15.2% | 11.2% | 11.9% |
| Gross Margin | 71.1% | 71.1% | 71.1% | 76.2% | 78.0% | 78.6% |
| Debt/Equity | 2.56 | 2.56 | 3.16 | 1.46 | 1.40 | 1.38 |
| Dividends/Share | $2.47 | $2.49 | $2.42 | $2.31 | $2.19 | $2.01 |
| Operating Income | 11.2B | 11.2B | -6.4B | 9.6B | 8.9B | 9.4B |
| Operating Margin | 23.3% | 23.3% | -13.3% | 21.3% | 19.3% | 20.3% |
| ROE | 38.2% | 40.5% | -54.8% | 27.3% | 20.4% | 19.5% |
| Shares Outstanding | 2,039M | 2,039M | 2,029M | 2,079M | 2,145M | 2,242M |
BRISTOL MYERS SQUIBB CO passes 3 of 9 quality checks, indicating weak fundamentals.
BRISTOL MYERS SQUIBB CO trades at 337.7x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average ROIC is 7.9% with a gross margin of 75.0%. Total shareholder yield (dividends) is 0.2%. At current prices, the estimated annualized return to fair value is +10.0%.
BRISTOL MYERS SQUIBB CO (BMYMP) has a current P/E ratio of 337.7, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
BRISTOL MYERS SQUIBB CO (BMYMP) has a 5-year average return on invested capital (ROIC) of 7.9%. This is below average and may indicate limited pricing power.
BRISTOL MYERS SQUIBB CO (BMYMP) has a market capitalization of $2.0T. It is classified as a mega-cap stock.
Yes, BRISTOL MYERS SQUIBB CO (BMYMP) pays a dividend with a trailing twelve-month yield of 0.25%.
Based on historical P/E analysis, BRISTOL MYERS SQUIBB CO (BMYMP) appears expensive. The current P/E of 337.7 is 2151% above its historical median of 15.0. The estimated fair value CAGR (P/E method) is 10.0%.
BRISTOL MYERS SQUIBB CO (BMYMP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
BRISTOL MYERS SQUIBB CO (BMYMP) reported annual revenue of $48.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
BRISTOL MYERS SQUIBB CO (BMYMP) has a net profit margin of 14.6%. This is a healthy margin.
BRISTOL MYERS SQUIBB CO (BMYMP) generated $12.8 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BRISTOL MYERS SQUIBB CO (BMYMP) has a debt-to-equity ratio of 2.56. This indicates higher leverage, which may increase financial risk.
BRISTOL MYERS SQUIBB CO (BMYMP) reported earnings per share (EPS) of $3.46 in its most recent fiscal year.
BRISTOL MYERS SQUIBB CO (BMYMP) has a return on equity (ROE) of 40.5%. This indicates the company generates strong returns for shareholders.
BRISTOL MYERS SQUIBB CO (BMYMP) has a 5-year average gross margin of 75.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for BRISTOL MYERS SQUIBB CO (BMYMP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BRISTOL MYERS SQUIBB CO (BMYMP) has a book value per share of $9.06, based on its most recent annual SEC filing.